| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Suzanne D Turner | Q39065389 |
| P2093 | author name string | Alexander DR | |
| P2860 | cites work | Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor | Q22009126 |
| Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation | Q24293167 | ||
| Nucleophosmin regulates the stability and transcriptional activity of p53 | Q24300176 | ||
| Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity | Q24522838 | ||
| Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5) | Q24595848 | ||
| Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery | Q27860586 | ||
| Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway | Q28140623 | ||
| Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death | Q28202067 | ||
| Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma | Q28250347 | ||
| Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA) | Q28588852 | ||
| AP-1: a double-edged sword in tumorigenesis | Q30014831 | ||
| Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma | Q33184109 | ||
| Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas | Q34037769 | ||
| Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis | Q34281241 | ||
| Translocations involving anaplastic lymphoma kinase (ALK). | Q34405439 | ||
| Anaplastic lymphoma kinase proteins in growth control and cancer | Q35750450 | ||
| A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1) | Q35788227 | ||
| Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma | Q38340761 | ||
| The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation | Q39444405 | ||
| Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. | Q39647760 | ||
| NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. | Q40482603 | ||
| Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma | Q40514814 | ||
| Identification of NPM-ALK interacting proteins by tandem mass spectrometry. | Q40589160 | ||
| NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a | Q40590126 | ||
| Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo | Q40610363 | ||
| Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase | Q40621401 | ||
| Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma | Q40761648 | ||
| CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. | Q41199240 | ||
| Involvement of Shc in insulin- and epidermal growth factor-induced activation of p21ras | Q41483761 | ||
| Interleukin 9 and its receptor: an overview of structure and function | Q41722206 | ||
| The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells | Q41927054 | ||
| A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma'). | Q42818441 | ||
| Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma | Q43665317 | ||
| NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. | Q44211040 | ||
| ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases | Q44451877 | ||
| The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model | Q44524417 | ||
| Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma | Q44559500 | ||
| Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. | Q44605512 | ||
| Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. | Q44605515 | ||
| Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity | Q44620758 | ||
| The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma | Q44848855 | ||
| ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma | Q49029662 | ||
| Overexpression of NPM–ALK induces different types of malignant lymphomas in IL-9 transgenic mice | Q57194341 | ||
| Humanbcr-abl gene has a lethal effect on embryogenesis | Q67715896 | ||
| ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases | Q73552593 | ||
| Fine-needle aspiration biopsy of anaplastic large cell lymphoma, small cell variant with prominent plasmacytoid features: case report | Q77551830 | ||
| Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals | Q77787348 | ||
| A Case of a Diffuse Large B-Cell Lymphoma of Plasmablastic Type Associated With the t(2;5)(p23;q35) Chromosome Translocation | Q79203551 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1128-1134 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? | |
| P478 | volume | 19 |
| Q34542109 | A novel role for IL-22R1 as a driver of inflammation |
| Q21129306 | ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma |
| Q36092957 | ALK-immunoreactive neoplasms. |
| Q38184584 | ALK-positive cancer: still a growing entity. |
| Q33851681 | Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization |
| Q36511310 | Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress |
| Q38996543 | Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. |
| Q37268913 | Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity |
| Q24312329 | Anaplastic lymphoma kinase: signalling in development and disease |
| Q48264091 | Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. |
| Q36546255 | Assays for pharmacodynamic analysis of histone deacetylase inhibitors |
| Q39442482 | Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants |
| Q35849172 | Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells |
| Q38106810 | Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma |
| Q40523569 | Challenging perspectives on the cellular origins of lymphoma |
| Q38303954 | Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis |
| Q24595585 | Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors |
| Q53376981 | Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: a Children's Cancer and Leukaemia Group Study. |
| Q54572569 | Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. |
| Q35575978 | Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. |
| Q64389376 | Induction of Chromosomal Translocations with CRISPR-Cas9 and Other Nucleases: Understanding the Repair Mechanisms That Give Rise to Translocations |
| Q35664324 | Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination |
| Q27851640 | Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas |
| Q53602581 | JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. |
| Q58701147 | Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion |
| Q36597677 | Nucleophosmin: a versatile molecule associated with hematological malignancies. |
| Q38858006 | Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma |
| Q36557523 | Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma |
| Q37039605 | The anaplastic lymphoma kinase in the pathogenesis of cancer |
| Q36917895 | The natural product avrainvillamide binds to the oncoprotein nucleophosmin |
| Q50981882 | The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells. |
Search more.